tirzepatide weight loss surmount-1 results percent weight loss 72 weeks reduction over time in tirzepatide‐treated participants by early response: Post hoc analysis in SURMOUNT‐1 - Ard - 2025 - Diabetes, Obesity and Metabolism Weight reduction with different doses

Quick Reference: Standard Protocol Community-reported standard protocol (self-reported

The gastrointestinal effects nausea, diarrhea, constipation, and vomiting are the most frequently reported adverse events in clinical trials for both drugs

The Science Behind Weight Loss Plateaus While your rate of weight loss will likely slow over time, its important to recognize that the dreaded semaglutide weight loss stall is not necessarily because of the medication losing potency, or your body developing a tolerance

PMCID: PMC2701135

Reality Tips to Maximize GLP-1 Medication Benefits Follow dosing instructions carefully: Start low, gradually increase as recommended

Your healthcare provider can help you assess the risks and benefits and decide on the best course of action